Auxilius Pharma Raises €3.3M to Redefine Drug Delivery
Auxilius Pharma Raises €3.3M to Redefine Drug Delivery with Value-Added Innovation
Investment, Biotech
💎 Polish virtual biotech Auxilius secures €3.3M to advance once-daily therapy for chronic angina and accelerate US market entry
Auxilius Pharma, a virtual biotech company developing Value Added Medications (VAMs), has secured €3.3M (PLN 15M) in fresh capital to support the clinical development of its lead candidate, AUX-001—a novel formulation targeting chronic stable angina. The funding round was led jointly by NanoGroup SA, a Warsaw Stock Exchange–listed biotech firm, and NCBR Investment Fund ASI S.A., marking a major strategic alignment in Poland’s biotech sector.
NanoGroup, investing €1.65M via its affiliated fund ffVC, now holds preferred shares in Auxilius Pharma. The remaining €1.65M comes from NCBR through a co-investment arrangement. This funding will directly support a Phase 1b clinical trial of AUX-001, with a Phase 2 trial planned for 2026. The drug employs proprietary technology that alters release kinetics to reduce dosing frequency, aiming to increase patient adherence and treatment efficacy in chronic cardiovascular conditions.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
Auxilius specializes in enhancing existing, clinically approved active pharmaceutical ingredients by formulating them into innovative delivery systems. Its platform improves pharmacokinetic profiles while reducing pill burden—one of the major causes of poor adherence in long-term therapies. In chronic angina, for example, traditional dosing regimens require multiple daily administrations, often leading to missed doses and suboptimal outcomes. AUX-001, however, leverages a controlled-release, once-daily design to simplify the regimen while maintaining therapeutic benefit.
The startup operates under the virtual biotech model—outsourcing R&D, manufacturing, and trials—allowing for high agility and cost efficiency. Its roadmap is oriented toward the US market, where it plans to submit a New Drug Application under the 505(b)(2) regulatory pathway by 2028. This pathway, which allows for a streamlined approval process of drugs that build upon previously approved therapies, reduces time-to-market and overall development risk. The model positions Auxilius as a capital-efficient innovator with reduced regulatory friction and stronger chances for early commercial partnerships.
Jędrzej Litwiniuk, CEO of Auxilius Pharma, emphasized the significance of the investment: “This is a breakthrough moment. Our strategic alignment with NanoGroup opens the door to new synergies and credibility in the eyes of global partners. With Phase 1b underway and Phase 2 scheduled for 2026, we anticipate a partnering agreement in 2027 with a key player in the US cardiology market. Many are actively scouting projects that are Phase 3–ready, and we plan to be exactly there by then.”
NanoGroup, the lead investor, is building a comprehensive biotech platform in Poland, spanning transplant innovation, aptamer technology, and now drug delivery systems. Its flagship project, NanOX, uses synthetic perfusates in normothermic perfusion systems to extend organ viability, a potentially transformative breakthrough in organ transplantation. This investment in Auxilius is consistent with NanoGroup’s broader strategy of building a vertically integrated biotech ecosystem focused on both breakthrough innovation and recurring revenue models.
“The strategic logic behind our investment is clear,” said Przemysław Mazurek, CEO of NanoGroup SA. “Auxilius has deep scientific roots, a scalable model, and a clinically relevant project with global commercial potential. This transaction reflects our commitment to shaping the biotech landscape in Central Europe by forming sustainable, high-growth alliances.”
According to Piotr Burliński, NanoGroup’s Business Director, the firm’s involvement is not limited to capital. “Our goal is to generate repeatable revenue streams through partnerships, not just equity appreciation. We see Auxilius as a long-term collaborator in delivering high-value therapeutics.”
Both companies are exploring further integration and shared R&D infrastructure. The collaboration marks another milestone in NanoGroup’s expansion, following its June 2025 acquisition of Pure Biologics’ aptamer platform and DOTO Medical. Together, these efforts represent Poland’s emerging bid to create a competitive biotech cluster capable of global reach.
Tags: Biotech, Investment
